Section 6: Education and Research

6ER-017

DIGITAL LITERACY OF PATIENTS IN A DAY HOSPITAL ONCOLOGY UNIT (submitted in 2019)

6ER-016

ECONOMIC VALUE OF UNUSED HIGH COST EXPERIMENTAL INFUSION DRUGS: A POTENTIAL SAVING FOR THE NATIONAL HEALTH SYSTEM (submitted in 2019)

6ER-015

RISKS OF PHARMACIST RECOMMENDED ANTIBIOTIC USE: GENERAL PUBLIC PERCEPTION (submitted in 2019)

6ER-014

EDUCATION OF PATIENTS RECEIVING OXYGEN THERAPY (submitted in 2019)

6ER-013

ENRICHED DEVELOPMENTAL BIOLOGY MOLECULAR PATHWAYS: IMPACT ON ANTIPSYCHOTIC INDUCED WEIGHT GAIN (submitted in 2019)

6ER-012

PERSISTENCE FOR DISEASE MODIFYING DRUGS FOR MULTIPLE SCLEROSIS (submitted in 2019)

6ER-011

REAL WORLD ADHERENCE TO MULTIPLE SCLEROSIS THERAPY (submitted in 2019)

6ER-010

THERAPEUTIC DRUG MONITORING OF TUMOUR NECROSIS FACTOR a INHIBITORS IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM A REAL WORLD SETTING (submitted in 2019)

6ER-009

TREATMENT PATTERNS IN MULTIPLE SCLEROSIS WITH DISEASE MODIFYING DRUGS (submitted in 2019)

6ER-008

STUDY OF THE USE OF DIMETHYL FUMARATE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN A THIRD LEVEL HOSPITAL (submitted in 2019)

6ER-007

PERSISTENCE AND SAFETY OF ADALIMUMAB IN PSORIASIS (submitted in 2019)

6ER-006

DIGITAL LITERACY IN MULTIPLE SCLEROSIS (submitted in 2019)

6ER-005

EFFECTIVENESS OF OMALIZUMAB AND BEE VENOM IMMUNOTHERAPY COMBINATION: CASE REPORT (submitted in 2019)

6ER-004

PRELIMINARY CLINICAL RESPONSE OF RIBOCICLIB AS A SINGLE AGENT IN ADVANCED BREAST CANCER: IN SEARCH OF NEW THERAPEUTIC INDICATIONS (submitted in 2019)

6ER-003

EFFECTIVENESS OF NEOADJUVANT TREATMENT IN LOCALLY ADVANCED BREAST CANCER (submitted in 2019)

Pages